Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Have heard that before. Too many games being played by mgmt right now.
$HEPA: Our SAVA moment is COMING.
And then watch what happens when we are trading well over $50/sh
ITS COMING !!!!!!!
You will be BLOWN AWAY
GO $HEPA
Buyout at $3 a share would work for me.
Major suppression going on here. Some believe a buyout deal has been made already. Trying to rob the shareholders out of a fair shake.
Last 10Q, $1.44 in cash per share
Now trading at less than cash, $1.43.
Insane.
The rumor was they are. It’s hard to get any truth out of this company right now while the syndicate is controlling the action.
When? November is a big NASH meeting. ST has some good info.
Any specifics on this meeting and if HEPA is presenting?
Hopefully he still holds this GEM. I hope for him. We will make money , just be patience. I added more today now my avg. is $1.99
Them lasers might need some alignment
Did the girlfriend axe you? The silence is defining.
BOMC, The company in the past has had a reverse stock split. Investors
fear management will do this again. Company will eventually need a
Phase 3 clinical trial so it is estimated results from such may not be
out until 2025-2026. If all goes well and substantial dilution is
avoided this stock could be a 100X gainer. The best way to play this
is to simply buy some stock and then sell call options until it is
called away. Might not get a 100X but could get you a double sooner
or later. Their only drug looks to be a winner if they can get it
through the gauntlet and perhaps reap the rewards of a BO.
298 share circus premarket
pure manipulation
As soon as the crime syndicate lets it go. November is a big NASH meeting. ST has some good info.
Chart looks to be at bottom...
when will it rise again?
Can anyone provide a short history of what is happening with this company?
Seems extremely undervalued and the science seems to work as far as I can tell.
Why are so many people voting against management? Is management OK?
Looking to buy 20K shares but don't understand why this company is so cheap and relations with management so bad.
This outcome should start the ball rolling. If the syndicate wants to make any money now they need that price higher. Failed 3 times trying to steal from us retail holders.
“Enough cash on hand to cover all costs of programs through end of Phase 2b (about 3 years in cash), assuming no expansion into other areas/projects”
Their words not mine
I don't know what happens here, we are at liquidation value right now. Incoming events, coming tuesday just a simple convention, and in November a full data readout.
Maybe M&A will happen, maybe not, we just don't know. Just stick to the potential of the science, that's it guys.
There is not a big risk of dilution, certainly not after the result of the vote.
It's clear that their initial target was to have 400m shares issuable, so they could issue the 320m shares on the shelf for the maximum of 350 million dollar they were cleared to. Let's say $1.10
Next play was the 240m shares issuable, so they had 160m shares to offer for the max of 350m dollar. Let's say $2.20
Now they have only 40m shares left to offer, for the max of 350m dollar. Let's say $9 bucks.
Conclusion, I don't know whether M&A will happen, maybe the ''Change of Control'' thing has to do with something else. Fact is, the potential here is HUGE, and the risk is LOW.
Low Risk, High Reward, as Warren likes 'em.
$HEPA
Vote for increased shares defeated. One for the good guys. Time to go higher.
No no.. still Holding almost 5k shares @ 2.09 avg.
Funny how shit coins have 3-32 billion dollar market caps vs hepion with all its research and scientists only has a 125 million mc at best lolololol and dilution coming short the shit out this fucker
Guess you sold and moved on as well?
Good news and more manipulation. Oh well we wait.
Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep. 21, 2021 4:19 PM ET Hepion Pharmaceuticals, Inc. (HEPA)
https://seekingalpha.com/article/4456410-additional-phase-iia-data-confirms-hepions-crv431-as-a-very-promising-nash-candidate-drug?mail_subject=francisco-javier-garcia-additional-phase-iia-data-confirms-hepion-s-crv431-as-a-very-promising-nash-candidate-drug&utm_campaign=rta-author-article&utm_content=link-0&utm_medium=email&utm_source=seeking_alpha
Given the direct relationship that the level of the Pro-C3 biomarker has with liver fibrosis, we are going to compare the behavior of the Pro-C3 biomarker in different trials carried out by companies with candidate drugs for NASH and thus be able to determine if the data provided by Hepion is promising.
Hepa is a empty shell with a notorious scammer CEO. They have paid tacto to pump their empty shell how they burn up the cash they made with dilution with salaries and bonuses. they do not even have a "0ffice" they contract out a investor relations firm. P.o boxes and cell phones is their over head!
“The decline in Pro-C3 that was observed in the AMBITION trial puts us well within the range of NASH data published by other companies with later-stage NASH drug candidates,” said Hepion’s Chief Medical Officer, Todd Hobbs MD.
“But notably, these declines in Pro-C3 with CRV431 occurred in only 4 weeks, compared to declines with other agents, where the changes occurred over several months.”
What is the significance of only 4 weeks?Sentence has a negative undertone.
I think the reason for all the delays and cancellations of the board meeting is because they didn’t have the votes to do it.
Guess we just vote NO ?
I could wait out the seller. But now their going to vote on adding 200 mil. Shares. What the hell is the CFO thinking?!
Diluted. I’ve been watching the seller holding it down.
I posted it last weekend
$HEPA: $110Milly Cash, No Debt, 76Milly OS
We doing just fine here.
Ambition looked good.
Party is only genna get much much better here.
A steal here at $1.54
GO $HEPA
Apparently just our hopes got shattered here...but at least we know this low floater will move
All that volume today for a damn penny. What the hell happened???? What's the short data like someone?
Filled gap.. now we can rise :)
Back to where we started…..
Patience is key here… stay strong
Whatever is going on in that call apparently is not enough to move the stock up.....so nothing earth shattering I'm guessing...
I’m working in the field today. Can you do a play by play?
Hearing anything that hasn't already been made public?
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2150
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |